Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: TCEA3 (ImmuneEditome ID:6920)

1. Gene summary of enriched editing regions for TCEA3

Gene summary

Gene information	Gene symbol	TCEA3
	Gene ID	6920
	GeneSynonyms	TFIIS\|TFIIS.H
	GeneCytomap	1p36.12
	GeneType	protein-coding
	GeneDescription	transcription elongation factor A protein 3\|rhabdomyosarcoma antigen MU-RMS-40.22\|transcription elongation factor A (SII), 3\|transcription elongation factor S-II protein 3\|transcription elongation factor TFIIS.h
	GeneModificationdate	20230329
	UniprotID	O75764;S4R419;S4R3M9
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr1:23381065-23383207:-	ENST00000450454.5	ENSG00000204219.8	TCEA3	exonic	FLAM_C,MIRb,MER91A,AluSp,AluY	chr1:23381065-23383207:-.alignment
chr1:23419545-23420549:-	ENST00000374601.6	ENSG00000204219.8	TCEA3	intronic	AluSz,AluJb,L1ME1	chr1:23419545-23420549:-.alignment
chr1:23419545-23420549:-	ENST00000450454.5	ENSG00000204219.8	TCEA3	intronic	AluSz,AluJb,L1ME1	chr1:23419545-23420549:-.alignment

Top

2. Tumor-specific enriched editing regions for TCEA3

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	Type	P	Boxplot
chr1:23381065-23383207:-	KIRC	EER	9.8643e-05
ENSG00000204219.8,TCEA3	KIRC	EAG	5.6192e-05
chr1:23381065-23383207:-	LIHC	EER	3.4359e-03
ENSG00000204219.8,TCEA3	LIHC	EAG	3.5040e-03
chr1:23381065-23383207:-	LUSC	EER	1.6296e-04
ENSG00000204219.8,TCEA3	LUSC	EAG	7.5316e-05

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
chr1:23381065-23383207:-	LIHC	Path	EER	2.9835e-04	1.1200e-03	0.1927
ENSG00000204219.8,TCEA3	LIHC	Path	EAG	3.5250e-04	1.2883e-03	0.1904

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events

cancer

TypeID

Pkm

Pcox_continuous

HR_continuous

KMPlot

Top

3. Enriched editing regions and immune related genes for TCEA3

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

More results

Top

4. Enriched editing regions and immune related splicing for TCEA3

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

ENSG00000204219.8,TCEA3

KIRC

EAG

ENSG00000109046.10

chr17

27306781:27306882:27309099:27309255

0.4044

6.2192e-11

1.1553e-14

0.4046

ADAR;AUH;BCCIP;BUD13;CSTF2T;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FKBP4;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHSRP;LARP7;LIN28B;LSM11;MOV10;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;U2AF2;UPF1;XRN2;YTHDC1

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_ANDROGEN_RESPONSE

ENSG00000204219.8,TCEA3

KIRC

EAG

ENSG00000099256.14

chr10

24856912:24856995:24858391:24858409

0.3039

2.8502e-08

9.8820e-13

0.4358

ADAR;CSTF2T;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FUS;GTF2F1;HNRNPC;HNRNPK;HNRNPL;IGF2BP1;IGF2BP2;KHSRP;LARP7;LIN28B;NONO;NOP56;NOP58;PRPF8;PTBP1;RBFOX2;SAFB2;SRSF1;SRSF7;TAF15;TARDBP;U2AF2;UPF1;YTHDC1

PRTFDC1

NK_cells_activated

GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE

ENSG00000204219.8,TCEA3

KIRC

EAG

ENSG00000100201.14

chr22

38487872:38488115:38492055:38492115

0.3897

3.2814e-10

7.9777e-15

0.4068

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS

ENSG00000204219.8,TCEA3

KIRC

EAG

ENSG00000147162.9

chrX

71544566:71544635:71547906:71548023

0.4174

3.9433e-12

8.7526e-16

0.4216

T_cells_follicular_helper

GSVA_HALLMARK_HEME_METABOLISM

chr1:23381065-23383207:-

KIRC

EER

ENSG00000147162.9

chrX

71544566:71544635:71547906:71548023

0.3999

1.0044e-10

2.9027e-14

0.4028

ACIN1;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX42;DDX54;DGCR8;DICER1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPC;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;LARP7;LIN28;LIN28B;MOV10;NOP56;NOP58;NPM1;PRPF8;RANGAP1;RBFOX2;RBM10;RBM22;SAFB2;SF3A3;SLTM;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TIA1;TIAL1;TNRC6A;TRA2A;U2AF1;U2AF2;UPF1;XRN2;YWHAG;ZNF184;TAF15

T_cells_follicular_helper

GSVA_HALLMARK_HEME_METABOLISM

chr1:23381065-23383207:-

KIRP

EER

ENSG00000102125.11

chrX

154418474:154419746:154420031:154420073

0.3840

3.4685e-06

6.6005e-10

0.4036

ACIN1;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX42;DDX54;DGCR8;DICER1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPC;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;LARP7;LIN28;LIN28B;MOV10;NOP56;NOP58;PRPF8;RANGAP1;RBFOX2;RBM10;SAFB2;SF3A3;SLTM;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TIA1;TIAL1;TRA2A;U2AF1;U2AF2;UPF1;XRN2;ZNF184;TAF15

Macrophages_M1

GSVA_HALLMARK_HEME_METABOLISM

ENSG00000204219.8,TCEA3

KIRP

EAG

ENSG00000102125.11

chrX

154418474:154419746:154420031:154420073

0.3895

2.0274e-06

2.6073e-10

0.4113

ADAR;AUH;BCCIP;BUD13;CSTF2T;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHSRP;LARP7;LIN28B;LSM11;MOV10;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;U2AF2;UPF1;XRN2;YTHDC1

Macrophages_M1

GSVA_HALLMARK_HEME_METABOLISM

ENSG00000204219.8,TCEA3

KIRP

EAG

ENSG00000171163.11

chr1

248857233:248857497:248857827:248857859

0.3536

1.1387e-06

3.3225e-10

0.4336

ADAR;AUH;BCCIP;BUD13;CSTF2T;DDX54;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHSRP;LARP7;LIN28B;LSM11;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;U2AF2;UPF1;XRN2

Macrophages_M1

GSVA_HALLMARK_PANCREAS_BETA_CELLS

chr1:23381065-23383207:-

KIRP

EER

ENSG00000171163.11

chr1

248857233:248857497:248857827:248857859

0.3548

1.1394e-06

4.3640e-10

0.4320

ACIN1;AUH;BCCIP;BUD13;CPSF6;CSTF2T;DDX42;DDX54;DGCR8;DICER1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPC;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;LARP7;LIN28;LIN28B;NOP56;NOP58;NPM1;PRPF8;RANGAP1;RBFOX2;RBM10;RBM22;SAFB2;SF3A3;SLTM;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TIA1;TNRC6A;TRA2A;U2AF1;U2AF2;UPF1;XRN2;YWHAG;ZNF184;TAF15

Macrophages_M1

GSVA_HALLMARK_PANCREAS_BETA_CELLS

More results

Top

5. Enriched editing regions and immune infiltration for TCEA3

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
chr1:23381065-23383207:-	ACC	EER	T_cells_follicular_helper	6.8737e-03	-0.3775
ENSG00000204219.8,TCEA3	ACC	EAG	T_cells_follicular_helper	4.0271e-03	-0.3997
chr1:23381065-23383207:-	BLCA	EER	Mast_cells_resting	1.0866e-02	0.2347
ENSG00000204219.8,TCEA3	BLCA	EAG	Mast_cells_resting	8.4362e-03	0.2415
chr1:23381065-23383207:-	BRCA	EER	NK_cells_activated	9.9377e-03	0.0881
ENSG00000204219.8,TCEA3	BRCA	EAG	B_cells_naive	2.6356e-02	0.0755
ENSG00000204219.8,TCEA3	COAD	EAG	Mast_cells_activated	4.2238e-02	0.1842
chr1:23381065-23383207:-	HNSC	EER	Mast_cells_resting	3.9397e-02	0.2266
ENSG00000204219.8,TCEA3	HNSC	EAG	Mast_cells_resting	3.9397e-02	0.2266
ENSG00000204219.8,TCEA3	KICH	EAG	Macrophages_M1	1.9094e-03	0.5608
chr1:23381065-23383207:-	KIRC	EER	NK_cells_activated	1.0838e-03	0.1778
ENSG00000204219.8,TCEA3	KIRC	EAG	NK_cells_activated	7.1560e-04	0.1829
chr1:23381065-23383207:-	KIRP	EER	T_cells_CD4_memory_resting	3.1777e-02	0.1452
chr1:23419545-23420549:-	KIRP	EER	Dendritic_cells_activated	2.4085e-05	0.7504
ENSG00000204219.8,TCEA3	KIRP	EAG	T_cells_CD4_memory_resting	2.7270e-02	0.1489
chr1:23381065-23383207:-	LIHC	EER	Dendritic_cells_activated	1.1233e-03	0.1857
ENSG00000204219.8,TCEA3	LIHC	EAG	Dendritic_cells_activated	1.0710e-03	0.1864
chr1:23381065-23383207:-	LUAD	EER	B_cells_naive	2.0263e-02	0.1257
ENSG00000204219.8,TCEA3	LUAD	EAG	B_cells_naive	3.5310e-02	0.1140
ENSG00000204219.8,TCEA3	LUSC	EAG	Monocytes	3.6778e-02	-0.1827
ENSG00000204219.8,TCEA3	MESO	EAG	Mast_cells_activated	4.2584e-02	0.3398
chr1:23381065-23383207:-	OV	EER	NK_cells_resting	1.3352e-03	0.2232
ENSG00000204219.8,TCEA3	OV	EAG	NK_cells_resting	2.5404e-03	0.2088
chr1:23381065-23383207:-	PCPG	EER	NK_cells_resting	8.8059e-04	0.6841
ENSG00000204219.8,TCEA3	PCPG	EAG	NK_cells_resting	8.8059e-04	0.6841
chr1:23381065-23383207:-	PRAD	EER	T_cells_CD4_memory_resting	5.7112e-04	-0.1580
chr1:23419545-23420549:-	PRAD	EER	T_cells_gamma_delta	2.2544e-02	0.1913
ENSG00000204219.8,TCEA3	PRAD	EAG	T_cells_CD4_memory_resting	1.6507e-03	-0.1442
chr1:23381065-23383207:-	READ	EER	B_cells_memory	4.5504e-02	0.3031
ENSG00000204219.8,TCEA3	READ	EAG	B_cells_memory	4.7356e-02	0.2973
chr1:23381065-23383207:-	SARC	EER	T_cells_follicular_helper	1.0594e-02	0.2365
ENSG00000204219.8,TCEA3	SARC	EAG	T_cells_follicular_helper	1.0735e-02	0.2361
chr1:23381065-23383207:-	STAD	EER	Plasma_cells	1.0745e-02	-0.1761
ENSG00000204219.8,TCEA3	STAD	EAG	Plasma_cells	1.2753e-02	-0.1677
chr1:23381065-23383207:-	THCA	EER	Eosinophils	1.6860e-03	0.1514
ENSG00000204219.8,TCEA3	THCA	EAG	Eosinophils	2.0409e-03	0.1487
ENSG00000204219.8,TCEA3	THYM	EAG	Dendritic_cells_resting	2.6183e-02	0.4841
ENSG00000204219.8,TCEA3	UCEC	EAG	Dendritic_cells_activated	3.1052e-02	0.3293
chr1:23381065-23383207:-	UCS	EER	Neutrophils	3.9282e-02	0.4147
ENSG00000204219.8,TCEA3	UCS	EAG	Neutrophils	4.0871e-02	0.4117

Top

6. Enriched editing regions and immune gene sets for TCEA3

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events	cancer	Type	E2M_P	Boxplot	CorP	CorR	CorrelationPlot
chr1:23381065-23383207:-	KIRP	EER	3.4696e-02		4.8304e-03	-0.1898
ENSG00000204219.8,TCEA3	KIRP	EAG	4.7574e-02		4.6176e-03	-0.1903
chr1:23381065-23383207:-	THCA	EER	4.8908e-02		1.0510e-04	-0.1864
ENSG00000204219.8,TCEA3	THCA	EAG	4.6840e-02		7.6954e-05	-0.1899

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events

cancer

Type

Buffa_P

Buffa_R

Ragnum_P

Ragnum_R

Winter_P

Winter_R

HALLMARK_P

HALLMARK_R

CorrelationPlot

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
ENSG00000204219.8,TCEA3	ACC	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EAG	6.1843e-03	-0.3820
chr1:23381065-23383207:-	ACC	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EER	1.0699e-02	-0.3580
ENSG00000204219.8,TCEA3	BLCA	GSVA_HALLMARK_MTORC1_SIGNALING	EAG	1.5223e-02	-0.2230
chr1:23381065-23383207:-	BLCA	GSVA_HALLMARK_MTORC1_SIGNALING	EER	1.7508e-02	-0.2193
ENSG00000204219.8,TCEA3	BRCA	GSVA_HALLMARK_MTORC1_SIGNALING	EAG	3.2907e-10	-0.2114
chr1:23419545-23420549:-	BRCA	GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE	EER	5.4327e-03	0.2010
chr1:23381065-23383207:-	BRCA	GSVA_HALLMARK_MTORC1_SIGNALING	EER	4.9695e-09	-0.1983
chr1:23381065-23383207:-	COAD	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EER	1.7032e-07	-0.4574
ENSG00000204219.8,TCEA3	COAD	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EAG	1.6440e-08	-0.4838
chr1:23381065-23383207:-	ESCA	GSVA_HALLMARK_MTORC1_SIGNALING	EER	1.2745e-04	-0.4106
ENSG00000204219.8,TCEA3	ESCA	GSVA_HALLMARK_MTORC1_SIGNALING	EAG	9.8102e-05	-0.4099
chr1:23381065-23383207:-	GBM	GSVA_HALLMARK_COAGULATION	EER	9.9456e-03	-0.4131
ENSG00000204219.8,TCEA3	GBM	GSVA_HALLMARK_COAGULATION	EAG	9.9524e-03	-0.4131
chr1:23381065-23383207:-	HNSC	GSVA_HALLMARK_UV_RESPONSE_UP	EER	4.6481e-04	-0.3757
ENSG00000204219.8,TCEA3	HNSC	GSVA_HALLMARK_UV_RESPONSE_UP	EAG	4.6481e-04	-0.3757
ENSG00000204219.8,TCEA3	KIRC	GSVA_HALLMARK_ANDROGEN_RESPONSE	EAG	3.0170e-12	-0.3670
chr1:23419545-23420549:-	KIRC	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	2.1066e-02	-0.2037
chr1:23381065-23383207:-	KIRC	GSVA_HALLMARK_ANDROGEN_RESPONSE	EER	1.3360e-10	-0.3416
chr1:23381065-23383207:-	KIRP	GSVA_HALLMARK_HEME_METABOLISM	EER	6.7820e-08	-0.3548
ENSG00000204219.8,TCEA3	KIRP	GSVA_HALLMARK_HEME_METABOLISM	EAG	2.7234e-08	-0.3639
chr1:23419545-23420549:-	KIRP	GSVA_HALLMARK_MYC_TARGETS_V2	EER	1.9054e-02	0.4748
ENSG00000204219.8,TCEA3	LIHC	GSVA_HALLMARK_COAGULATION	EAG	8.7651e-04	-0.1896
chr1:23381065-23383207:-	LIHC	GSVA_HALLMARK_COAGULATION	EER	8.4146e-04	-0.1902
ENSG00000204219.8,TCEA3	LUAD	GSVA_HALLMARK_ANDROGEN_RESPONSE	EAG	3.5697e-08	-0.2929
chr1:23381065-23383207:-	LUAD	GSVA_HALLMARK_ANDROGEN_RESPONSE	EER	2.4180e-07	-0.2752
ENSG00000204219.8,TCEA3	LUSC	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EAG	3.6303e-06	-0.3921
chr1:23381065-23383207:-	LUSC	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EER	7.2393e-06	-0.3821
chr1:23381065-23383207:-	OV	GSVA_HALLMARK_KRAS_SIGNALING_UP	EER	1.5438e-04	-0.2619
ENSG00000204219.8,TCEA3	OV	GSVA_HALLMARK_KRAS_SIGNALING_UP	EAG	2.3676e-04	-0.2529
chr1:23419545-23420549:-	OV	GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION	EER	1.2207e-02	0.5031
ENSG00000204219.8,TCEA3	PAAD	GSVA_HALLMARK_G2M_CHECKPOINT	EAG	2.2108e-02	-0.2424
chr1:23381065-23383207:-	PAAD	GSVA_HALLMARK_G2M_CHECKPOINT	EER	3.9351e-02	-0.2201
chr1:23381065-23383207:-	PCPG	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EER	3.5859e-02	-0.4715
ENSG00000204219.8,TCEA3	PCPG	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EAG	3.5859e-02	-0.4715
chr1:23381065-23383207:-	PRAD	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	2.1211e-05	-0.1944
ENSG00000204219.8,TCEA3	PRAD	GSVA_HALLMARK_UV_RESPONSE_DN	EAG	7.1674e-05	-0.1813
ENSG00000204219.8,TCEA3	READ	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EAG	7.7261e-04	0.4832
chr1:23381065-23383207:-	READ	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EER	5.3087e-04	0.5011
chr1:23381065-23383207:-	SARC	GSVA_HALLMARK_INFLAMMATORY_RESPONSE	EER	1.2203e-02	-0.2320
ENSG00000204219.8,TCEA3	SARC	GSVA_HALLMARK_INFLAMMATORY_RESPONSE	EAG	1.1146e-02	-0.2349
ENSG00000204219.8,TCEA3	STAD	GSVA_HALLMARK_COMPLEMENT	EAG	4.2836e-03	-0.1919
chr1:23419545-23420549:-	STAD	GSVA_HALLMARK_BILE_ACID_METABOLISM	EER	4.0269e-05	0.6514
chr1:23381065-23383207:-	STAD	GSVA_HALLMARK_INFLAMMATORY_RESPONSE	EER	2.8826e-03	-0.2052
chr1:23381065-23383207:-	THCA	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EER	4.6159e-08	-0.2604
ENSG00000204219.8,TCEA3	THCA	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EAG	3.7765e-08	-0.2620
ENSG00000204219.8,TCEA3	UCEC	GSVA_HALLMARK_MYC_TARGETS_V1	EAG	4.4279e-02	0.3083

Top

7. Enriched editing regions and drugs for TCEA3

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
chr1:23381065-23383207:-	ACC	CEP.701	EER	5.7995e-03	0.3848
ENSG00000204219.8,TCEA3	ACC	CEP.701	EAG	7.9824e-03	0.3710
ENSG00000204219.8,TCEA3	BLCA	Bleomycin	EAG	1.5064e-02	0.2233
chr1:23381065-23383207:-	BLCA	Bleomycin	EER	1.6923e-02	0.2204
ENSG00000204219.8,TCEA3	BRCA	CMK	EAG	4.0121e-04	0.1202
chr1:23381065-23383207:-	BRCA	CMK	EER	6.5482e-04	0.1165
ENSG00000204219.8,TCEA3	CESC	AZD.0530	EAG	2.8398e-02	0.1625
chr1:23381065-23383207:-	CESC	AZD.0530	EER	4.4480e-02	0.1492
chr1:23381065-23383207:-	COAD	BIRB.0796	EER	3.4548e-03	-0.2660
ENSG00000204219.8,TCEA3	COAD	AZ628	EAG	1.0918e-03	0.2922
chr1:23381065-23383207:-	ESCA	IPA.3	EER	8.0814e-03	-0.2924
ENSG00000204219.8,TCEA3	ESCA	AZD6482	EAG	1.3237e-02	-0.2677
ENSG00000204219.8,TCEA3	GBM	AZ628	EAG	8.2399e-04	0.5198
chr1:23381065-23383207:-	GBM	AZ628	EER	8.2790e-04	0.5196
ENSG00000204219.8,TCEA3	HNSC	Bicalutamide	EAG	1.3246e-02	0.2709
chr1:23381065-23383207:-	HNSC	Bicalutamide	EER	1.3246e-02	0.2709
ENSG00000204219.8,TCEA3	KIRC	BMS.708163	EAG	1.0032e-04	0.2097
chr1:23381065-23383207:-	KIRC	BMS.708163	EER	3.4277e-04	0.1945
chr1:23419545-23420549:-	KIRC	GNF.2	EER	2.3789e-02	-0.1997
ENSG00000204219.8,TCEA3	KIRP	BX.795	EAG	2.7649e-04	0.2429
chr1:23419545-23420549:-	KIRP	CMK	EER	4.5251e-02	-0.4123
chr1:23381065-23383207:-	KIRP	BX.795	EER	3.9950e-04	0.2372
ENSG00000204219.8,TCEA3	LIHC	GDC0941	EAG	2.6235e-06	0.2661
chr1:23381065-23383207:-	LIHC	GDC0941	EER	2.6179e-06	0.2662
chr1:23381065-23383207:-	LUAD	ABT.888	EER	3.2957e-04	-0.1933
ENSG00000204219.8,TCEA3	LUAD	ABT.888	EAG	1.2917e-04	-0.2058
chr1:23381065-23383207:-	LUSC	Dasatinib	EER	3.5108e-04	0.3088
ENSG00000204219.8,TCEA3	LUSC	Dasatinib	EAG	2.1979e-04	0.3175
ENSG00000204219.8,TCEA3	MESO	FH535	EAG	3.6352e-04	0.5618
chr1:23381065-23383207:-	MESO	FH535	EER	8.6355e-04	0.5310
ENSG00000204219.8,TCEA3	OV	BX.795	EAG	2.3520e-02	0.1574
chr1:23419545-23420549:-	OV	GSK269962A	EER	1.5544e-02	-0.4880
chr1:23381065-23383207:-	OV	BX.795	EER	1.7118e-02	0.1668
chr1:23381065-23383207:-	PAAD	CGP.082996	EER	1.2387e-02	0.2656
ENSG00000204219.8,TCEA3	PAAD	CGP.082996	EAG	1.3313e-02	0.2615
ENSG00000204219.8,TCEA3	PCPG	CHIR.99021	EAG	3.7788e-02	0.4672
chr1:23381065-23383207:-	PCPG	CHIR.99021	EER	3.7788e-02	0.4672
ENSG00000204219.8,TCEA3	PRAD	BMS.708163	EAG	3.1436e-06	0.2122
chr1:23419545-23420549:-	PRAD	CEP.701	EER	5.5136e-04	0.2863
chr1:23381065-23383207:-	PRAD	BMS.708163	EER	1.1477e-06	0.2217
chr1:23381065-23383207:-	READ	LFM.A13	EER	1.9994e-02	-0.3496
ENSG00000204219.8,TCEA3	READ	LFM.A13	EAG	1.8027e-02	-0.3511
ENSG00000204219.8,TCEA3	SARC	CI.1040	EAG	1.4889e-03	0.2917
chr1:23381065-23383207:-	SARC	CI.1040	EER	1.7692e-03	0.2872
ENSG00000204219.8,TCEA3	SKCM	BI.2536	EAG	2.1579e-02	0.3496
chr1:23381065-23383207:-	SKCM	BI.2536	EER	2.1579e-02	0.3496
chr1:23419545-23420549:-	STAD	AZD6482	EER	1.6466e-02	-0.4145
chr1:23381065-23383207:-	STAD	Erlotinib	EER	1.9584e-02	-0.1614
ENSG00000204219.8,TCEA3	STAD	Erlotinib	EAG	1.9128e-02	-0.1579
ENSG00000204219.8,TCEA3	THCA	Metformin	EAG	1.0514e-09	-0.2894
chr1:23381065-23383207:-	THCA	Metformin	EER	1.0111e-09	-0.2897
ENSG00000204219.8,TCEA3	THYM	BMS.754807	EAG	3.9577e-02	0.4522
ENSG00000204219.8,TCEA3	UCEC	Epothilone.B	EAG	1.8330e-03	-0.4616
ENSG00000204219.8,TCEA3	UCS	Bortezomib	EAG	1.9012e-02	0.4656
chr1:23381065-23383207:-	UCS	Bortezomib	EER	2.0375e-02	0.4610

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType